Sara L. Van Driest

7.2k total citations · 2 hit papers
106 papers, 3.3k citations indexed

About

Sara L. Van Driest is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Sara L. Van Driest has authored 106 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pharmacology, 29 papers in Pediatrics, Perinatology and Child Health and 27 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sara L. Van Driest's work include Pharmacogenetics and Drug Metabolism (31 papers), Pharmaceutical studies and practices (24 papers) and Cardiomyopathy and Myosin Studies (14 papers). Sara L. Van Driest is often cited by papers focused on Pharmacogenetics and Drug Metabolism (31 papers), Pharmaceutical studies and practices (24 papers) and Cardiomyopathy and Myosin Studies (14 papers). Sara L. Van Driest collaborates with scholars based in United States, Denmark and Germany. Sara L. Van Driest's co-authors include Michael J. Ackerman, Steve R. Ommen, Bernard J. Gersh, A. Jamil Tajik, Dan M. Roden, Melissa L. Will, Josh F. Peterson, Joshua C. Denny, Vlad C. Vasile and Rick A. Nishimura and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Sara L. Van Driest

100 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacogenomics

2019 238 citations Dan M. Roden, Josh F. Peterson et al. profile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

2020 194 citations Sara L. Van Driest, Larisa H. Cavallari et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sara L. Van Driest United States	29	1.5k	864	638	462	445	106	3.3k
Suzette J. Bielinski United States	33	844 0.5×	844 1.0×	549 0.9×	381 0.8×	440 1.0×	154	3.7k
Elvira Grandone Italy	41	1.6k 1.1×	637 0.7×	621 1.0×	574 1.2×	732 1.6×	226	6.5k
Sabine M. J. M. Straus Netherlands	31	1.3k 0.8×	764 0.9×	221 0.3×	450 1.0×	188 0.4×	108	3.7k
Niclas Eriksson Sweden	23	1.2k 0.8×	486 0.6×	2.1k 3.3×	247 0.5×	507 1.1×	67	4.2k
Arlene B. Chapman United States	27	788 0.5×	757 0.9×	352 0.6×	329 0.7×	104 0.2×	89	2.6k
Loes E. Visser Netherlands	36	690 0.4×	913 1.1×	872 1.4×	418 0.9×	331 0.7×	124	4.3k
Ulrich Broeckel United States	37	633 0.4×	1.1k 1.3×	987 1.5×	678 1.5×	358 0.8×	95	3.9k
Rashmi R. Shah United Kingdom	33	1.4k 0.9×	1.4k 1.6×	518 0.8×	242 0.5×	153 0.3×	85	3.4k
Vera H.M. Deneer Netherlands	31	1.9k 1.2×	465 0.5×	1.1k 1.8×	562 1.2×	224 0.5×	88	4.5k
Roland Valdes United States	29	822 0.5×	840 1.0×	571 0.9×	220 0.5×	119 0.3×	77	2.8k

Countries citing papers authored by Sara L. Van Driest

Since Specialization

Citations

This map shows the geographic impact of Sara L. Van Driest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara L. Van Driest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara L. Van Driest more than expected).

Fields of papers citing papers by Sara L. Van Driest

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara L. Van Driest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara L. Van Driest. The network helps show where Sara L. Van Driest may publish in the future.

Co-authorship network of co-authors of Sara L. Van Driest

This figure shows the co-authorship network connecting the top 25 collaborators of Sara L. Van Driest. A scholar is included among the top collaborators of Sara L. Van Driest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara L. Van Driest. Sara L. Van Driest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shi, Mingjian, et al.. (2025). A polygenic score for height identifies an unmeasured genetic predisposition among pediatric patients with idiopathic short stature. Genome Medicine. 17(1). 23–23. 1 indexed citations

Karnes, Jason H., et al.. (2024). Using electronic health records for clinical pharmacology research: Challenges and considerations. Clinical and Translational Science. 17(7). e13871–e13871.

Ramsey, Laura B., Cynthia A. Prows, Sonya Tang Girdwood, & Sara L. Van Driest. (2023). Current Practices in Pharmacogenomics. Pediatric Clinics of North America. 70(5). 995–1011. 2 indexed citations

Driest, Sara L. Van, Jamie R. Robinson, Henry H. Ong, et al.. (2023). Developing and evaluating pediatric phecodes (Peds-Phecodes) for high-throughput phenotyping using electronic health records. Journal of the American Medical Informatics Association. 31(2). 386–395. 4 indexed citations

Gong, Wu, et al.. (2023). Pediatric Persistent Inflammation, Immunosuppression, and Catabolism Syndrome Prevalence in Sepsis-Related Mortalities. CHEST Journal. 164(5). 1204–1215. 7 indexed citations

Birdwell, Kelly A., et al.. (2022). Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data. British Journal of Clinical Pharmacology. 88(6). 2863–2874. 1 indexed citations

Bagheri, Minoo, Cecilia P. Chung, Alyson L. Dickson, et al.. (2022). White blood cell ranges and frequency of neutropenia by Duffy genotype status. Blood Advances. 7(3). 406–409. 10 indexed citations

Driest, Sara L. Van, Evan C. Sommer, Aida Yared, et al.. (2022). Direct-to-patient telehealth equity: Reaching diverse pediatric populations in primary care.. Families Systems & Health. 41(1). 61–67. 3 indexed citations

Dickson, Alyson L., Wenjian Yang, W. Dale Plummer, et al.. (2022). Race, Genotype, and Azathioprine Discontinuation. Annals of Internal Medicine. 175(8). 1092–1099. 16 indexed citations

10.

Edwards, Todd L., et al.. (2022). Association between nitric oxide synthase 3 genetic variant and acute kidney injury following pediatric cardiac surgery. American Heart Journal. 254. 57–65. 1 indexed citations

11.

James, Nathan T., Richard M. Caprioli, Todd L. Edwards, et al.. (2021). Population pharmacokinetic analysis of dexmedetomidine in children using real‐world data from electronic health records and remnant specimens. British Journal of Clinical Pharmacology. 88(6). 2885–2898. 11 indexed citations

12.

Luzum, Jasmine A., Natasha Petry, Annette K. Taylor, et al.. (2021). Moving Pharmacogenetics Into Practice: It’s All About the Evidence!. Clinical Pharmacology & Therapeutics. 110(3). 649–661. 40 indexed citations

13.

Kannankeril, Prince J., et al.. (2021). Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population. Clinical Pharmacology & Therapeutics. 111(4). 896–908. 9 indexed citations

14.

Gillon, Jessica, et al.. (2018). Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin–Tazobactam or Cefepime: A Cohort Study. Journal of the Pediatric Infectious Diseases Society. 8(3). 221–227. 6 indexed citations

15.

Driest, Sara L. Van, Anushi Shah, Hua Xu, et al.. (2013). Opioid Use After Cardiac Surgery in Children With Down Syndrome*. Pediatric Critical Care Medicine. 14(9). 862–868. 20 indexed citations

16.

Weeke, Peter, Jessica Delaney, Jonathan D. Mosley, et al.. (2013). QT variability during initial exposure to sotalol: experience based on a large electronic medical record. EP Europace. 15(12). 1791–1797. 19 indexed citations

17.

Driest, Sara L. Van, et al.. (2005). Gene-specific modifying effects of pro-LVH polymorphisms involving the renin–angiotensin–aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. European Heart Journal. 26(22). 2457–2462. 72 indexed citations

18.

Driest, Sara L. Van, Steve R. Ommen, A. Jamil Tajik, Bernard J. Gersh, & Michael J. Ackerman. (2005). Yield of Genetic Testing in Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings. 80(6). 739–744. 118 indexed citations

19.

Driest, Sara L. Van, Vlad C. Vasile, Steve R. Ommen, et al.. (2005). Reply. Journal of the American College of Cardiology. 46(2). 381–382.

20.

Driest, Sara L. Van, Steve R. Ommen, Vlad C. Vasile, et al.. (2004). 1032-122 Comprehensive mutational analysis of myosin binding protein C in 389 unrelated patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 43(5). A165–A165. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact